Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active von Willebrand factor VHH study in platelet adhesion and aggregation
NL-OMON48403Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Mar 2019
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Syn-VWFA1 in von Willebrand disease type 2B (VWD2B), sponsored by Maastricht University. Primary endpoint: Active von Willebrand factor levels. Started Mar 2019; status: active, not recruiting.
02
Drugs
Syn-VWFA1
03
Conditions
von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on NL-OMON48403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48403.